FDA granted Fast Track designation for A2B543 for the treatment of germline heterozygous HLA-A*02 adults with recurrent unresectable, locally advanced, or metastatic solid tumors that express MSLN and have lost HLA-A*02 expression April 7, 2026
First Patient dosed in Ph 1 Trial of CLIO-8221 in Advanced HER2-Expressing Solid Tumors March 31, 2026
Voro Therapeutics and Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Gen Tumor-Activated ADCs March 24, 2026
Novartis entered into an agreement with Synnovation Therapeutics to acquire SNV4818 for HR+/HER2- breast cancer and other solid tumor indications March 24, 2026
Crossbow Therapeutics raised $77 million in Series B financing to support completion of CROSSCHECK‑001 Ph 1 clinical trial of CBX‑250, and accelerate development of additional T‑Bolt™ immunotherapies March 24, 2026
GlycoNex Inc. and Nippon Kayaku Enter Collaboration to Advance Next-Gen ADC Candidate GNX201-ADC March 24, 2026
Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Gen T-Cell Engager Therapies March 24, 2026
Ph 1a data of TOS-358 in heavily pretreated patients with PI3Kα-mutant metastatic breast cancer and other solid tumors presented March 24, 2026
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. March 10, 2026
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio March 10, 2026
NMPA approves IND application for HLX97 for the treatment of advanced or metastatic solid tumors March 10, 2026
FDA approves IND application for Ph 1 trial of KGX105 monotherapy in locally advanced or metastatic solid tumors March 10, 2026
FDA approves IND application for KST-0651 for Ph 1 trial in Advanced Solid Tumors including pancreatic cancer, CRC, NSCLC, and others March 10, 2026
FDA approves IND application for GNTbm-38 for Ph 1 trial in Advanced Solid Tumors and R/R PTCL March 10, 2026
IND Application filed for ML-016 for Advanced Solid Tumors with Lung and/or Liver Mets March 10, 2026
Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors February 25, 2026
Sift Biosciences Announces Oversubscribed $3.7M Pre-seed Financing to Advance Next-gen T-cell Immunotherapy Platform February 25, 2026
